The Symbicort 100/3 pressurised metered-dose inhaler delivers 80 micrograms of budesonide and 2.25 micrograms of formoterol fumarate dihydrate per puff, from a metered dose of 100 micrograms and 3 micrograms respectively.
Symbicort 100/3 is indicated in adults and adolescents from 12 years for the regular treatment of asthma where use of a combination (inhaled corticosteroid and long-acting ß2 agonist) is appropriate, including:
- in patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short-acting ß2 agonists, and
- in patients already adequately controlled on both inhaled corticosteroids and long-acting ß2 agonists.
Symbicort 100/3 can be used for both maintenance and maintenance/reliever therapy.
The existing 200/6 Symbicort pMDI is licensed for use only in patients with COPD. Symbicort 100/3 pMDI is not approved for COPD.